Achillion Pharmaceuticals (NASDAQ:ACHN) posted its earnings results on Thursday. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.02, Fidelity Earnings reports.
NASDAQ ACHN traded up $0.01 on Friday, reaching $6.36. The stock had a trading volume of 1,598,800 shares, compared to its average volume of 2,042,478. The firm has a fifty day moving average of $4.93 and a two-hundred day moving average of $3.79. Achillion Pharmaceuticals has a 1-year low of $1.29 and a 1-year high of $6.46. The company has a market cap of $888.45 million, a P/E ratio of -12.47 and a beta of 1.67.
In other Achillion Pharmaceuticals news, CEO Joseph Truitt sold 133,484 shares of the company’s stock in a transaction on Wednesday, October 16th. The stock was sold at an average price of $6.37, for a total value of $850,293.08. Following the transaction, the chief executive officer now directly owns 103,734 shares of the company’s stock, valued at approximately $660,785.58. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 4.58% of the company’s stock.
Achillion Pharmaceuticals Company Profile
Achillion Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis.
Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.